Cargando…

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melo, Miguel, Gavina, Cristina, Silva-Nunes, José, Andrade, Luís, Carvalho, Davide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317280/ https://www.ncbi.nlm.nih.gov/pubmed/34315528 http://dx.doi.org/10.1186/s13098-021-00698-5

Ejemplares similares

Psoriasis & cardiovascular morbidity: The missing links?
por: Ganguly, Satyaki, et al.
Publicado: (2017)

Are genes the missing link to detect and prognosticate RA-ILD?
por: Vermant, Marie, et al.
Publicado: (2023)

Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials: Perspective on GLP-1 RA and SGLT-2i therapies
por: Ludwig, Lisa, et al.
Publicado: (2020)

Revisiting the cardiovascular risk of hydroxychloroquine in RA
por: Pers, Yves-Marie, et al.
Publicado: (2020)

Hyperhomocysteinemia and Cardiovascular Disease: Is the Adenosinergic System the Missing Link?
por: Paganelli, Franck, et al.
Publicado: (2021)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
por: Meiring, S., et al.
Publicado: (2022)

Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease
por: Luo, Jing, et al.
Publicado: (2023)

Expedition to the missing link: Long noncoding RNAs in cardiovascular diseases
por: Yeh, Chih-Fan, et al.
Publicado: (2020)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2018)

Cardiovascular risk factor management in patients with RA compared to matched non-RA patients
por: Alemao, Evo, et al.
Publicado: (2016)

Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients
por: Du, Lixin, et al.
Publicado: (2022)

The definition and measurement of heterogeneity
por: Nunes, Abraham, et al.
Publicado: (2020)

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2019)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Long-term cardiovascular complications following sepsis: is senescence the missing link?
por: Merdji, Hamid, et al.
Publicado: (2021)

Missed Opportunities to Address Cardiovascular Disease Risk Factors amongst Adults Attending an Urban HIV Clinic in South Africa
por: Rabkin, Miriam, et al.
Publicado: (2015)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

Myostatin: The Missing Link between Sarcopenia and Cardiovascular Disease in Chronic Kidney Disease?
por: Morioka, Tomoaki
Publicado: (2020)

Adiponectin System (Rescue Hormone): The Missing Link between Metabolic and Cardiovascular Diseases
por: Aljafary, Meneerah Abdulrahman, et al.
Publicado: (2022)

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2020)

The Interplay between Cardiovascular Risk, Cardiovascular Events, and Disease Activity in Primary Sjögren’s Syndrome: Is Uric Acid the Missing Link?
por: Alunno, Alessia, et al.
Publicado: (2023)

Cardiovascular disease in the QUEST-RA study, 10 years later
por: Naranjo, Antonio, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
por: Morton, Jedidiah I., et al.
Publicado: (2022)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?
por: Marx, Nikolaus, et al.
Publicado: (2018)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
por: Menghini, Rossella, et al.
Publicado: (2023)

Adverse Pregnancy Outcomes: The Missing Link in Discovering the Role of Lactation in Cardiovascular Disease Prevention
por: Lane, Abbi, et al.
Publicado: (2022)

Cardiovascular involvement in COVID-19: not to be missed
por: Rocco, Isadora S., et al.
Publicado: (2020)

Ideal Cardiovascular Health in Young Adults With Established Cardiovascular Diseases
por: Leopold, Jane A., et al.
Publicado: (2022)

Heterogeneity in cardiovascular death or hospitalization for heart failure benefits with flozins is linked to weight
por: Ghosal, Samit, et al.
Publicado: (2023)

PREVALENCE AND OUTCOMES OF CARDIOVASCULAR COMPLICATIONS AMONGST COVID-19 PATIENTS
por: Aedma, Surya Kiran, et al.
Publicado: (2021)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Wallia, Amisha, et al.
Publicado: (2023)

Addressing the Bias in Cardiovascular Care: Missed & Delayed Diagnosis of Cardiovascular Disease in Women
por: Johnson, Heather M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nkppofgb5j3rb5c38ipnlk1c40